Health Trials

About this trial

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®).

In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

Eligibility criteria

Qualifiers

ER+HER2- breast cancer

Premenopausal and age <=50

T1 or T2

N1 including micrometastasis

Disqualifiers

Postmenopausal women

ER-negative breast cancer

Trial design

Treatments tested in this trial

  • Ovarian function suppression with endocrine treatments

Treatment groups

418 Participants
are divided into 1 treatment group

Locations

2
Gangnam Severance Hospital06229, SeoulKorea, South Korea
Seoul National University Hospital Seoul South Korea

Sponsors and collaborators

Gangnam Severance Hospital

Lead sponsor

Seoul National University

Collaborator

Source ClinicalTrials.gov